Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 4/20 | 0.57 |
| ▸ | SERPINE1 | P05121 | 8/20 | 0.57 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.54 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.49 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6352355 | 0.84 | CA9 (0.53) | CA9SERPINE1CA2AKR1C4AKR1C3 | |
| SCHEMBL11820343 | 0.76 | MRGPRX4 (0.54) | — | |
| SCHEMBL6351321 | 0.75 | SERPINE1 (0.89) | CA9SERPINE1CA2AKR1C4AKR1C3 | |
| SCHEMBL10339426 | 0.74 | SERPINE1 (0.69) | CA9SERPINE1CA2 | |
| SCHEMBL421010 | 0.73 | SERPINE1 (1.00) | CA9SERPINE1CA2AKR1C4AKR1C3 | |
| SCHEMBL420616 | 0.73 | SERPINE1 (1.00) | CA9SERPINE1CA2AKR1C4AKR1C3 | |
| SCHEMBL1308303 | 0.73 | TP53 (0.78) | CA9SERPINE1CA2AKR1C4AKR1C3 | |
| SCHEMBL6350712 | 0.73 | AKR1C2 (0.63) | AKR1C4AKR1C3AKR1C2AKR1C1KCNK2 | |
| SCHEMBL19554134 | 0.72 | SERPINE1 (0.68) | CA9SERPINE1CA2AKR1C4AKR1C3 | |
| SCHEMBL19554148 | 0.72 | DHODH (0.70) | CA9SERPINE1CA2AKR1C4AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113450-A1 | Antibacterial agents | PHARMACIA & UPJOHN COMPANY | 2005-05-26 | — | — | US | claimed |
| WO-2004018414-A2 | ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| US-20050113450-A1 | Antibacterial agents | PHARMACIA & UPJOHN COMPANY | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113450-A1 | Antibacterial agents | CLPP, SPOUT1, SAMHD1 | CA9 2085/4885SERPINE1 1929/4885CA2 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.